Prevalence of polypharmacy in pregnancy: a systematic review

Asth A Anand,1 Katherine Phillips,1 Anuradha Subramanian,1 Siang Ing Lee,1 Zhaonan Wang,1 Rebecca McCowan,2 Utkarsh Agrawal,3 Adeniyi Frances Fagbamigbe,3,4,5 Catherine Nelson-Piercy,6 Peter Brocklehurst,1 Christine Damase-Michel,7 Maria Loane,8 Krishnarajah Nirantharakumar 1,9 Amaya Azcoaga-Lorenzo10 3 on behalf of the MuM-PreDiCT Group

ABSTRACT

Objectives The use of medications among pregnant women has been rising over the past few decades but the reporting of polypharmacy has been sporadic. The objective of this review is to identify literature reporting the prevalence of polypharmacy among pregnant women, the prevalence of multimorbidity in women taking multiple medications in pregnancy and associated effects on maternal and offspring outcomes.

Design MEDLINE and Embase were searched from their inception to 14 September 2021 for interventional trials, observational studies and systematic reviews reporting on the prevalence of polypharmacy or the use of multiple medications in pregnancy were included.

Data on prevalence of polypharmacy, prevalence of multimorbidity, combinations of medications and pregnancy and offspring outcomes were extracted. A descriptive analysis was performed.

Results Fourteen studies met the review criteria. The prevalence of women being prescribed two or more medications during pregnancy ranged from 4.9% (4.3%–5.5%) to 62.4% (61.3%–63.5%), with a median of 22.5%. For the first trimester, prevalence ranged from 4.9% (4.7%–5.14%) to 33.7% (32.2%–35.1%). No study reported on the prevalence of multimorbidity, or associated pregnancy outcomes in women exposed to polypharmacy.

Conclusion There is a significant burden of polypharmacy among pregnant women. There is a need for evidence on the combinations of medications prescribed in pregnancy, how this specifically affects women with multiple long-term conditions and the associated benefits and harms.

Tweetable abstract Our systematic review shows significant burden of polypharmacy in pregnancy but outcomes for women and offspring are unknown.

PROSPERO registration number CRD42021223966.

INTRODUCTION

Medications may be taken in pregnancy for the management of pregnancy-related symptoms (such as nausea and vomiting), pre-existing maternal health conditions or pregnancy-related complications.1–3 The use of medications among pregnant women has been rising over the past few decades,4–6 which could be attributed to a rise in the prevalence of maternal comorbidities, obesity and, in the UK and other high-income countries, a rise in the average maternal age.7,8 With this, the use of multiple medications is also likely to increase.3 While many studies have assessed overall medication use among pregnant women, fewer studies have focused on polypharmacy.

Polypharmacy is broadly defined as the use of multiple medications by a single patient, but various definitions are found in the literature. A systematic review of polypharmacy definitions found that studies reported various numerical definitions (ranging from the use of two or more medication to eleven or more medications) and some also incorporated duration or appropriateness of therapy.9 As the number of medications taken together increases, medication interactions and adverse events are expected to increase also. It has been reported that, as the number of medications prescribed together increases, as does the number of potentially serious drug–drug interactions.10 The use of multiple medication has been reported among specific subpopulation of pregnant women, such as women with psychiatric illness, epilepsy or...
HIV. However, the polypharmacy rate among general population of pregnant women is not as well understood. Drug pharmacokinetics are altered in pregnancy due to physiological changes in the expectant mothers. For example, expanded plasma volume and maternal body fat in pregnancy increases the volume of distribution for hydrophilic and lipophilic drugs leading to lower plasma concentration. Moreover, increased hepatic and renal clearance during pregnancy can lead to subtherapeutic drug concentrations.14 15

However, few clinical trials are undertaken among pregnant women due to concerns around maternal and fetal safety.16 17 It is therefore, unknown whether polypharmacy during pregnancy will worsen known side effects, result in novel adverse events or, indeed, have a synergistic or beneficial effect.10 Understanding these effects will allow clinicians and women to make more informed decisions about continuing, starting or stopping medications before and during pregnancy.

The objective of this systematic review was to assess the published literature reporting on the prevalence of polypharmacy among pregnant women, the prevalence of multimorbidity in women taking multiple medications in pregnancy and the effect of multiple medication use on maternal and offspring outcomes.

METHODS
A systematic review of the literature was performed in order to identify relevant studies examining the prevalence of polypharmacy in pregnancy, the most common medication combination, rate of multimorbidity and outcomes among women exposed to polypharmacy.

Protocol and registration
 Protocol for this systematic review has been published on PROSPERO (protocol ID CRD42021223966, available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021223966).18

Eligibility criteria
 We included interventional trials, observational studies (cohort studies and case–control studies) and systematic reviews reporting the prevalence of polypharmacy or use of multiple medications in pregnant women, where the prevalence of polypharmacy could be extracted from tables or figures. The study authors’ definition of polypharmacy was used and we retained the study authors’ eligibility criteria for whether over-the-counter (OTC) medications were included. Where polypharmacy was not defined by the authors of the individual studies, we defined polypharmacy to mean the use of two or more medications.

Exclusion criteria
 We excluded studies focused on specific subpopulations of pregnant women instead of general prevalence of polypharmacy (such as pregnant women with specific medical conditions, or with high-risk pregnancies), as we were interested in the population-based prevalence. We excluded expert opinions, conference abstract, case report, narrative review, laboratory and animal studies. Studies based on non-pregnant women were excluded and unpublished data were not sought.

We did not exclude non-English papers. For any non-English paper identified, native speaker would extract data where possible. Where this was not possible, two independent reviewers (AA and AA-L) extracted the data using an online translation service (Google Translate).

Outcome measurement
 The primary outcome was prevalence of polypharmacy, as defined by the authors, or the use of two or more medications, where polypharmacy was not defined by the authors.

We also assessed the prevalence of multimorbidity and maternal or offspring outcomes among women exposed to polypharmacy. The individual studies’ definition of multimorbidity was used where specified. Where the definition of multimorbidity was not specified by the authors, it was defined as the presence of two or more long-term health conditions, including mental health conditions.

Search strategy
 MEDLINE was searched for relevant papers from 1946 to 14 September 2021 and Embase was searched from 1974 to 14 September 2021. A librarian helped to develop the search strategy. The full search strategy for Embase is provided in online supplemental appendix S1.

Study selection and data extraction
 Study selection was conducted in two phases. In the first phase, title and abstracts were screened by two independent reviewers against the eligibility criteria (AA screened all papers, SIL, AS, AF, UA and ZW were the second reviewers). We retrieved full-text papers for all potentially eligible studies. In the second phase, full-text papers were assessed by two authors independently (AA and AA-L) against the eligibility criteria. For all eligible studies, two authors (AA and AA-L) independently extracted the data using a piloted data extraction form, and assessed the risk of bias. Discrepancies were reviewed and resolved by a third independent reviewer (ZW).

Data items extracted included: purpose of the study, setting, recruitment, inclusion and exclusion criteria, participant demographics (age, ethnicity, parity, deprivation), definition of polypharmacy, prevalence of polypharmacy, classification system for grouping medications, list of health conditions, follow-up length, any secondary outcomes, funding and conflict of interest.

We used the Newcastle-Ottawa critical appraisal checklist for observational studies to assess risk of bias in the individual studies during the data extraction stage.19

Summary measures and results synthesis
 Results are presented as descriptive analysis. The primary outcome is presented as proportion or prevalence. We stratified the analysis according to the various definitions of polypharmacy from the primary studies (eg, two or
more medications) and the setting (primary or secondary care). Given the heterogenous nature of the studies, statistical pooling and analysis was not possible. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for reporting of systematic reviews has been followed (online supplemental appendix S2).

**Patient and public involvement**

Patients were not involved in the development of the research question, study design or selection of outcome measures.

**RESULTS**

**Study selection**

We screened 2228 titles and abstracts. Of those, 46 papers were subjected to detailed evaluation in full-text screening, and 14 met inclusion criteria. The main reasons for exclusion were an inadequate method of reporting prevalence of polypharmacy or reporting on specific subpopulation of pregnant women. The results from each step of the review process are documented in a PRISMA flow diagram (figure 1).

![Figure 1](http://bmjopen.bmj.com/) 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. Adapted from: Page et al. For more information, visit: http://www.prisma-statement.org/.
Study characteristics

Table 1 shows the characteristics of the included studies. Studies were published between 1991 and 2020. The study populations ranged between 369 and 981 392. Six studies examined the prevalence of polypharmacy using administrative data, seven used surveys to collect self-reported medication use. One study used administrative data for prescription medications and self-report for the use of OTC medications.

In seven studies, women were recruited from hospitals (either birth hospital or antenatal clinic). In the other seven studies, participants were sampled from a national registry or population-based database (such as pharmacy records).

Mitchell et al reported results from two different cohorts: Birth Defect Study (BDS) and National Birth Defects Prevention Study (NBDDS). Both studies contain data from mothers of babies born with birth defects and from a control group of mothers of babies born without birth defects. Mitchell et al reported data from both cases and controls in the BDS and from just the controls of the NBDDS. As pregnancies of mothers of babies born with birth defects are unlikely to be representative of the general population of pregnant women, only data from NBDDS were included in the results of this review.

Risk of bias within studies

Most of the study cohorts were considered representative of the population they were sampling from. Most studies ascertained pregnancy status using hospital or pharmacy records or from birth registries, which were considered likely to be accurate. van Gelder et al and Schirm et al used a pharmacy database to identify all children born within a given timeframe. Women of reproductive age living at the same address as the child were identified in the database and their prescription data was collected for the 270 days before the child’s date of birth. There is a chance that women could have been misclassified as pregnant if the child was not living with their biological mother.

As discussed above, seven studies relied solely on self-reported medication use to measure outcomes, introducing the potential for recall bias. The follow-up period was considered adequate for each study. Nine studies reported multiple medication use across the entire pregnancy, while three studies reported for early pregnancy (first trimester) only. Obadeji et al and Tinker et al employed a cross-sectional design and included women across all trimesters. Follow-up rates were considered adequate for all studies, with no study having significant numbers of subjects lost to follow-up. Online supplemental table S1 shows the outcome of the risk of bias assessment.

Prevalence of polypharmacy

The prevalence of polypharmacy ranged from 0.2% to 62.4%, with a median value of 12.3%. The exclusion of OTC drugs does not change the spread of the prevalence of polypharmacy.

Prevalence by polypharmacy definition

The prevalence of polypharmacy, defined as the use of two or more medications, ranged from 4.9% (4.3%–5.5%) to 61.3% (61.3%–63.5%) based on eight papers, with a median value of 22.5% (20.8%–25.7%) (figure 2). Only two studies explicitly defined polypharmacy. Olesen et al defined it as the use of four or more medications (prevalence 2.7%) and Haas et al defined it as the use of five or more medications (prevalence 13%).

Other studies did not define polypharmacy, but stratified results by the number of medications taken (figure 2). Mitchell et al and Gomes et al did not define polypharmacy and only reported the use of four or more medications (15.7%) and six or more drugs (24.9%), respectively. Malm et al reported that 0.2% of women purchased 10 or more different medications during the whole period of pregnancy. Due to heterogeneity within the data, meta-analysis was not undertaken.

Prevalence of polypharmacy by trimester

Two studies, Obadeji et al and Zhang et al, reported polypharmacy use across the whole pregnancy and also subdivided into trimesters. For these two studies, polypharmacy prevalence across the whole pregnancy has been summarised. Obadeji et al reported a prevalence of 50.0% (95% CI 21.1% to 79.0%) in the first trimester compared with a prevalence of 38.3% (95% CI 33.4% to 43.2%) across all three trimesters. Zhang et al reported a prevalence of 3.8% (95% CI 3.1% to 4.6%) in the first trimester compared with a prevalence of 9.2% (95% CI 8.3% to 10.2%) across all three trimesters. Due to the design and nature of the study, Van Gelder et al, Cleary et al and Buitendijk et al have reported medication use during early pregnancy or the first trimester period only, reporting polypharmacy prevalence of 4.9% (95% CI 4.7% to 5.1%), 11.5% (95% CI 11.3% to 11.8%) and 33.7% (95% CI 32.2% to 35.1%) respectively. In a cross-sectional study, Tinker et al cover medication use in the last 30 days only but across the whole pregnancy. Olesen et al cover a period from 12 weeks prenatal to 12 weeks postpartum in the analysis.

Prevalence of polypharmacy by medications included

While most of the studies reported any possible medication use, van Gelder et al report only the teratogenic medications used and not all possible medications.

OTC medications

Eight studies include OTC medications in their analysis—results for polypharmacy prevalence, subdivided by inclusion of OTC drugs, are shown in figure 4. Reported prevalence of polypharmacy for studies that included OTC medications ranged from 4.9% (Mitchell et al 95% CI 4.3% to 5.5%) to 38.3% (Obadeji et al 95% CI 33.3% to 43.3%). Reported prevalence of polypharmacy for studies that excluded OTC medications

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Country/location</th>
<th>Inclusion criteria</th>
<th>Source (administrative data/self-reported)</th>
<th>Total number of pregnancies</th>
<th>Trimester studied</th>
<th>Polypharmacy definition used in study</th>
<th>Definition of polypharmacy used in review</th>
<th>Medications included or excluded</th>
<th>Prevalence reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buitendijk and Bracken&quot;</td>
<td>Retrospective survey</td>
<td>USA</td>
<td>All women who made their first prenatal visit to private obstetric or midwifery practice, a health maintenance organisation, or a hospital clinic and were scheduled for delivery at Yale New Haven Hospital</td>
<td>Self-report</td>
<td>4186</td>
<td>Early pregnancy (first trimester)</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Included OTC medications Excluded vitamins and minerals</td>
<td>33.70%</td>
</tr>
<tr>
<td>Olesen et al&quot;</td>
<td>Retrospective cohort</td>
<td>Denmark</td>
<td>Primiparous women identified through Danish National Birth Registry</td>
<td>Administrative data</td>
<td>16 001</td>
<td>Across the three trimesters</td>
<td>More than three medications</td>
<td>≥4 (as defined by the authors)</td>
<td>Excluded vitamins and minerals</td>
<td>2.70%</td>
</tr>
<tr>
<td>Gomes et al&quot;</td>
<td>Retrospective survey</td>
<td>Brazil</td>
<td>Pregnant women who gave birth in one of five participating hospitals</td>
<td>Self-report</td>
<td>1620</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥6</td>
<td>Included OTC medications Excluded vitamins and minerals</td>
<td>24.90%</td>
</tr>
<tr>
<td>Malm et al&quot;</td>
<td>A retrospective, register-based cohort study</td>
<td>Finland</td>
<td>All women who applied for maternal grants in 1999 and the mother has visited a maternity clinic before the end of the fourth month</td>
<td>Administrative record</td>
<td>43 470</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥10</td>
<td>Included some, but not all, OTC medications</td>
<td>0.20%</td>
</tr>
<tr>
<td>Schirm et al&quot;</td>
<td>Cross-sectional study</td>
<td>Netherlands</td>
<td>Female person (15–50 years older than child) at the same address as child aged 0–5 years, with no other female at the address</td>
<td>Administrative data</td>
<td>7500</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Excluded OTC medications</td>
<td>62.41%</td>
</tr>
<tr>
<td>Refuerzo et al&quot;</td>
<td>Prospective observational</td>
<td>USA</td>
<td>Women who gave birth at a single, university-based, tertiary-care hospital</td>
<td>Self-report</td>
<td>418</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Included OTC medications</td>
<td>33.50%</td>
</tr>
<tr>
<td>Cleary et al&quot;</td>
<td>Retrospective cohort</td>
<td>Ireland</td>
<td>Pregnancy booking and midwife care at tertiary level hospital</td>
<td>Self-report</td>
<td>61 252</td>
<td>Early pregnancy (first trimester)</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Included OTC medications</td>
<td>11.53%</td>
</tr>
<tr>
<td>Mitchell et al (NBDPS Study Arm Reported)&quot;</td>
<td>Cross-sectional study</td>
<td>USA and Canada</td>
<td>NBDPS study controls were randomly selected from birth certificates or from birth hospitals</td>
<td>Self-report</td>
<td>5008</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥4</td>
<td>Included OTC medications</td>
<td>4.90%</td>
</tr>
<tr>
<td>van Gelder et al&quot;</td>
<td>Retrospective cohort study</td>
<td>Netherlands</td>
<td>Female person (15–50 years older than child) at the same address as child aged 0–5 years, with no other female at the address</td>
<td>Administrative record</td>
<td>32 016</td>
<td>First trimester</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Excluded vitamins and minerals</td>
<td>4.90%</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Country/location</th>
<th>Inclusion criteria</th>
<th>Source (adminstrative data/self-reported)</th>
<th>Total number of pregnancies</th>
<th>Trimester studied</th>
<th>Polypharmacy definition used in study</th>
<th>Definition of polypharmacy used in review</th>
<th>Medications included or excluded</th>
<th>Prevalence reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tinker et al&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Cross-sectional surveys</td>
<td>USA</td>
<td>Non-institutionalised civilian women aged 15–44 years</td>
<td>Self-report</td>
<td>1350</td>
<td>Prior 30 days (pregnancies across three trimesters)</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Excluded vitamins and minerals</td>
<td>6.10%</td>
</tr>
<tr>
<td>Haas et al&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Prospective longitudinal cohort study</td>
<td>USA</td>
<td>Primiparous women, aged 13 years or above, in the first trimester</td>
<td>Self-report</td>
<td>9546</td>
<td>Across the three trimesters</td>
<td>≥5 medications during the same epoch</td>
<td>≥5 (as defined by the authors)</td>
<td>Included OTC medications</td>
<td>13%</td>
</tr>
<tr>
<td>Ingstrup et al&lt;sup&gt;25&lt;/sup&gt;</td>
<td>Population-based descriptive study</td>
<td>Denmark</td>
<td>Pregnancies ending in live-born singletons during 1997–2012 to women aged between 15 and 55 years</td>
<td>Administrative record</td>
<td>981,392</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>None mentioned</td>
<td>42.74%</td>
</tr>
<tr>
<td>Zhang et al&lt;sup&gt;27&lt;/sup&gt;</td>
<td>Retrospective cohort study</td>
<td>China</td>
<td>Singleton deliveries, mothers aged between 12 and 54 years</td>
<td>Administrative data</td>
<td>7946 (2896 pregnancies covering all 3 trimesters)</td>
<td>Across the three trimesters</td>
<td>Polypharmacy not defined by author</td>
<td>≥2</td>
<td>Included OTC medications</td>
<td>9.19%</td>
</tr>
<tr>
<td>Obadeji et al&lt;sup&gt;29&lt;/sup&gt;</td>
<td>Cross-sectional study</td>
<td>Nigeria</td>
<td>All consecutive consenting women who came for outpatient antenatal care at a secondary healthcare facility</td>
<td>Administrative data for prescription drug and self-report for OTC</td>
<td>369</td>
<td>Cross-sectional (pregnancies across three trimesters)</td>
<td>Polypharmacy not defined by author</td>
<td>≥3</td>
<td>Included OTC medications</td>
<td>38.30%</td>
</tr>
</tbody>
</table>

NBDPS, National Birth Defects Prevention Study; OTC, over-the-counter.
ranged from 0.2% (Malm et al (95% CI 0.2% to 0.2%)) to 62.4% (Schirm et al (95% CI 61.3% to 63.5%)). Of note, Malm et al include some but not all OTC medications, as some medications were reimbursable and therefore were included in the national medication prescription register used for the study.24

Exclusion of vitamins and minerals
Five studies specifically excluded vitamins and minerals (such as folic acid and iron) from the study design.20 22 23 28 30 The definition of routine prenatal vitamins or minerals was determined by the authors of the original studies. Haas et al analysed medication use, when vitamins and minerals were included and excluded. When including vitamins and minerals, Haas et al report 30.5% (95% CI 29.6% to 31.5%) of women use five or more medication; whereas, only 13% (95% CI 12.3% to 13.7%) use five or more medications if vitamins and minerals are excluded.6

Medications used during pregnancy
The most commonly prescribed or taken medications described in the studies were antiemetics,4 6 23 antibiotics6 27–31 analgesia6 23 and antacids23 29 31 and vitamins or supplements5 28 31. However, no studies specified which medications were used in combination or were used by women exposed to polypharmacy.

Figure 2  Forest plot showing prevalence of polypharmacy, subdivided by the definition of polypharmacy (number of medications taken).
Multimorbidity and maternal or offspring outcomes

No studies were found describing which conditions women who were exposed to polypharmacy were treated for, and none specify how many women had multimorbidity or long-term illness. No studies were found that reported on maternal or offspring outcomes.

DISCUSSION

Main findings

Studies of multiple medication use in pregnancy reported a wide range in the prevalence of polypharmacy. Where the definition of polypharmacy was two or more medications only, the prevalence of polypharmacy ranged from 5% to 62%. However, the definition of polypharmacy was varied, and most studies were not considered truly representative of all pregnant women.

Strengths and limitations

This systematic review has several important strengths. We developed a structured and substantial review of the literature, according to preplanned and comprehensive search terms with the help of a librarian, who is trained to undertake searches in large database repositories. Screening was conducted according to a rigorous inclusion and exclusion criteria, and we used two independent reviewers for data extraction to minimise bias. Two databases were searched: MEDLINE and Embase. We did not limit our search to studies published in the English language to minimise language bias, although specific databases in languages other than English were not included.

There are limited studies specifically assessing polypharmacy in pregnancy. There is no consensus on the definition of polypharmacy and polypharmacy is often not explicitly defined in the studies. Where polypharmacy is defined, the definition varies from study to study. Only two studies in this systematic review subdivide polypharmacy use in different trimesters. Exclusion of routine prenatal vitamins is often determined by individual authors. Inclusion of OTC medications is variable and often determined by the data available.

The main caveat from these studies is that it is not clear whether the use of multiple medication in pregnancy was simultaneous or sequential. Additionally, prescription
and dispensation of medications do not equate to compliance. Qualitative studies show that women are less likely to use medications when pregnant, especially if potential risks to the fetus and benefits to the mother have not been adequately communicated.64 In majority of the studies identified in this systematic review, pregnancy was confirmed retrospectively or identified using birth records. Thus, not all pregnancies were captured and pregnancies resulting in terminations, miscarriages or stillbirth, were excluded. These pregnancy outcomes are clinically important and the use of multiple medications in these groups warrants further assessment.

While some of the studies outline common medications used by pregnant women overall, none of the studies describe the combinations of medications used in pregnancy. Pregnant women have been described as drug orphans, as they are often excluded from clinical trials. The maternal and offspring outcomes following medication exposure during pregnancy are often determined through retrospective observational studies.16 17 The association between rates of miscarriage and preterm birth and medications used during pregnancy have been described in women with major psychiatric illnesses13; however, none of the studies assessing polypharmacy in this systematic review evaluate the effect of taking multiple medication for the women and their offspring.

**Interpretation**

The finding of 5%–62% of pregnant women taking two or more medications is in keeping with a previous systematic review of the literature evaluating individual-level exposures to prescription medications in pregnancy. This review, which included only studies from developed (Organisation for Economic Co-operation and Development (OECD)) countries, found 27%–93% of women filled at least one prescription during pregnancy reflecting high medication use during pregnancy.65 The findings of this review should be interpreted with caution. As discussed above, the literature is not necessarily representative of the general pregnant population, inclusion of certain medications was variable and, where polypharmacy was defined, there were differences in the definitions used. This variation is in keeping with the findings of a systematic review of definitions of polypharmacy in older people.9 This review also found that, in some instances, safety and appropriateness of medications were taken into account when defining polypharmacy. This is an important consideration in pregnancy, although, as discussed, there is often not adequate safety information available.

Despite this, the median value of one in five women taking two or more medications, indicates that a significant proportion of women are potentially exposed to multiple medication in pregnancy. The lack of studies into combinations of medications taken during pregnancy and the effects of polypharmacy on maternal and offspring outcomes highlights the urgent need for further research in this area.

**CONCLUSION**

The reported prevalence of polypharmacy among pregnant women varies based on the number of...
medications counted in the definition, the trimester considered and the types of medications included. Commonly, only pregnancies resulting in live birth are reported in studies assessing polypharmacy. This systematic review shows relatively large burden of polypharmacy among pregnant women and highlights the need to evaluate the outcomes for these women and for their offspring. This is especially relevant for women with multiple, long-term conditions, who are more likely to need multiple medications.

Author affiliations
1Institute of Applied Health Research, University of Birmingham, Birmingham, UK
2University of Glasgow, Glasgow, UK
3Division of Population and Behavioural Sciences, University of Saint Andrews School of Medicine, St Andrews, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria
2University of Glasgow, Glasgow, UK
4Epidemiology and Medical Statistics, University of Ibadan, Ibadan, Nigeria

Acknowledgements
The authors thank Ms. Vicki Cormie, senior librarian (Academic Liaison) at University of St. Andrews for help with the search strategy. The authors thank Professor Helen Dolk for advice and comments on the manuscript.

Collaborators

Contributors
KN, AA and AA-L conceived the study and designed the protocol. AA and AA-L performed the literature search. AA, ZW, AS, SIL, UA, AF, RM and AA-L selected the studies and extracted the relevant information. AA synthesised the data and wrote the first draft of the paper. AA, KP, SIL, AS, RM, CN-P, PB, CD-M, ML, KN and AA-L critically reviewed previous drafts of the paper. AA is the guarantor of the review.

Funding
This work was funded by the Strategic Priority Fund ‘Tackling multimorbidity at scale’ programme (grant number MPS/14/1432/1) delivered by the Medical Research Council and the National Institute for Health Research in partnership with the Economic and Social Research Council and in collaboration with the Engineering and Physical Sciences Research Council.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not applicable.

Ethics approval
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
No data are available.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Katherine Phillips http://orcid.org/0000-0003-0674-605X
Siang Ing Lee http://orcid.org/0000-0002-2332-5452
Beatriz A McCowan http://orcid.org/0000-0001-892X
Krishnaraj Nirancharakumar http://orcid.org/0000-0002-6816-1279
Amaya Azoaga-Lorenzo http://orcid.org/0000-0003-3307-878X

REFERENCES
7 MuM-PreDICt. Epidemiology of pre-existing multimorbidity in pregnant women in the UK in 2018: a cross sectional study using CPRD SAIL and SMR. 2021. Available: https://docs.google.com/document/d/1mZ9i9SGciCZlIX8Q2RoY9e9pg6lQYiabtd/edit


51 Glavind J, Greve T, de Wolff MG, et al. Medication used in Denmark in the late phase of labor-do we know what we are doing? *Sex Reprod Healthc* 2020:25:100155.


